168 related articles for article (PubMed ID: 18829743)
1. Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus.
Carey BL; Ahmed M; Puckett S; Lyles DS
J Virol; 2008 Dec; 82(24):12104-15. PubMed ID: 18829743
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.
Ahmed M; Cramer SD; Lyles DS
Virology; 2004 Dec; 330(1):34-49. PubMed ID: 15527832
[TBL] [Abstract][Full Text] [Related]
3. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.
Felt SA; Droby GN; Grdzelishvili VZ
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566376
[TBL] [Abstract][Full Text] [Related]
5. Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses.
Udayakumar TS; Betancourt DM; Ahmad A; Tao W; Totiger TM; Patel M; Marples B; Barber G; Pollack A
Mol Cancer Res; 2020 Aug; 18(8):1232-1243. PubMed ID: 32366674
[TBL] [Abstract][Full Text] [Related]
6. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers.
Fehl DJ; Ahmed M
Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863
[TBL] [Abstract][Full Text] [Related]
7. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo.
Connor JH; Naczki C; Koumenis C; Lyles DS
J Virol; 2004 Sep; 78(17):8960-70. PubMed ID: 15308693
[TBL] [Abstract][Full Text] [Related]
8. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
Chang G; Xu S; Watanabe M; Jayakar HR; Whitt MA; Gingrich JR
J Urol; 2010 Apr; 183(4):1611-8. PubMed ID: 20172545
[TBL] [Abstract][Full Text] [Related]
9. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ
Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247
[TBL] [Abstract][Full Text] [Related]
10. SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis.
Muscolini M; Castiello L; Palermo E; Zevini A; Ferrari M; Olagnier D; Hiscott J
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092575
[TBL] [Abstract][Full Text] [Related]
11. Antiviral activity of doxycycline against vesicular stomatitis virus in vitro.
Wu ZC; Wang X; Wei JC; Li BB; Shao DH; Li YM; Liu K; Shi YY; Zhou B; Qiu YF; Ma ZY
FEMS Microbiol Lett; 2015 Nov; 362(22):. PubMed ID: 26459887
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death.
Zhang KX; Matsui Y; Hadaschik BA; Lee C; Jia W; Bell JC; Fazli L; So AI; Rennie PS
Int J Cancer; 2010 Aug; 127(4):830-8. PubMed ID: 19957332
[TBL] [Abstract][Full Text] [Related]
13. An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells.
Hastie E; Cataldi M; Steuerwald N; Grdzelishvili VZ
Virology; 2015 Sep; 483():126-40. PubMed ID: 25965802
[TBL] [Abstract][Full Text] [Related]
14. Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains.
Diallo JS; Vähä-Koskela M; Le Boeuf F; Bell J
Methods Mol Biol; 2012; 797():127-40. PubMed ID: 21948474
[TBL] [Abstract][Full Text] [Related]
15. Restricted replication of vesicular stomatitis virus in T lymphocytes is coincident with a deficiency in a cellular protein kinase required for viral transcription.
Sleat DE; Chikkala NF; Gautam S; Banerjee AK
J Gen Virol; 1992 Dec; 73 ( Pt 12)():3125-32. PubMed ID: 1335023
[TBL] [Abstract][Full Text] [Related]
16. A genome-wide small interfering RNA screen identifies host factors required for vesicular stomatitis virus infection.
Lee AS; Burdeinick-Kerr R; Whelan SP
J Virol; 2014 Aug; 88(15):8355-60. PubMed ID: 24829348
[TBL] [Abstract][Full Text] [Related]
17. Robust kinetics of an RNA virus: Transcription rates are set by genome levels.
Timm C; Gupta A; Yin J
Biotechnol Bioeng; 2015 Aug; 112(8):1655-62. PubMed ID: 25726926
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.
Shinozaki K; Ebert O; Suriawinata A; Thung SN; Woo SL
J Virol; 2005 Nov; 79(21):13705-13. PubMed ID: 16227290
[TBL] [Abstract][Full Text] [Related]
19. Vesiculopolins, a New Class of Anti-Vesiculoviral Compounds, Inhibit Transcription Initiation of Vesiculoviruses.
Ogino M; Fedorov Y; Adams DJ; Okada K; Ito N; Sugiyama M; Ogino T
Viruses; 2019 Sep; 11(9):. PubMed ID: 31540123
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4.
Moon J; Kaowinn S; Cho IR; Min DS; Myung H; Oh S; Kaewpiboon C; Kraemer OH; Chung YH
Biochem Biophys Res Commun; 2016 Jun; 474(3):428-434. PubMed ID: 27150631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
